Contract Development and Manufacturing (CDMO) Market to Surge from US$ 150.19 Billion in 2024 to US$ 280.07 Billion by 2033 at a CAGR of 7.4% | Top Companies are Catalent Inc, Recipharm AB, Jubilant Pharmova Limited.

The global contract development and manufacturing (CDMO) market reached US$ 150.19 billion in 2024 and is expected to reach US$ 280.07 billion by 2033, growing at a CAGR of 7.4% during the forecast period 2025-2033, according to DataM Intelligence report.

According to DataM Intelligence has published a new research report on "Contract Development and Manufacturing (CDMO) Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

The Contract Development and Manufacturing (CDMO) market comprises companies that provide outsourced drug development and manufacturing services to pharmaceutical and biotechnology firms. CDMOs support activities such as formulation development, clinical trial material production, and commercial-scale manufacturing. The market enables pharma companies to reduce costs, accelerate time-to-market, and focus on core research activities. Increasing drug complexity, biologics development, and capacity constraints are key growth drivers. The CDMO market is expanding rapidly due to rising demand for flexible, scalable, and regulatory-compliant manufacturing solutions.

📌 Download Free Sample PDF:- https://datamintelligence.com/download-sample/contract-development-and-manufacturing-market?rk
➣ Recent Developments:

✅ In December 2025, global pharmaceutical companies increased outsourcing to CDMOs to accelerate drug development timelines.
Demand rose for integrated services spanning formulation, clinical manufacturing, and commercial scale-up.
This trend reflects the need for speed, flexibility, and cost efficiency.

✅ In October 2025, CDMOs expanded capacity for biologics and advanced therapies, including cell and gene treatments.
Investments focused on high-containment facilities and single-use technologies.
These upgrades support complex and high-value pharmaceutical pipelines.

✅ In August 2025, strategic partnerships between CDMOs and biotech firms gained momentum across early-stage development.
Collaborations aim to de-risk R&D and shorten time to market.
This model is increasingly favored by virtual and mid-sized biotechs.

✅ In June 2025, digitalization initiatives accelerated within CDMO operations to improve efficiency and compliance.
Manufacturers adopted AI-driven analytics, MES, and real-time quality monitoring.
These technologies enhance transparency and regulatory readiness.

✅ In April 2025, CDMOs broadened service offerings to include end-to-end support from preclinical to commercial manufacturing.
This integrated approach simplifies supply chains for pharma sponsors.
It also strengthens long-term client relationships.

✅ In March 2025, sustainability became a stronger focus in CDMO manufacturing strategies.
Providers invested in energy-efficient processes and waste reduction programs.
Sustainable operations are increasingly influencing partner selection decisions.

📌 Get Customization in the report as per your requirements: https://datamintelligence.com/customize/contract-development-and-manufacturing-market?rk

➣ Top Industry Players:

Catalent Inc, Recipharm AB, Jubilant Pharmova Limited, Thermo Fisher Scientific Inc., Boehringer Ingelheim International GmbH, IQVIA, Syneos Health, Parexel International (MA) Corporation, Curia Global, Inc., NextPharma Technologies among others.

➣ Market Segments:

by Service Type (Active Pharmaceutical Ingredient (API) Manufacturing, Finished Dosage Formulation (FDF) Development and Manufacturing, Secondary Packaging)

by Research Phase (Pre-Clinical, Phase I, Phase II, Phase III, Phase IV)

by End User (Pharmaceutical Companies, Contract Research Organizations (CROs), Generic Pharmaceutical Companies

📌 Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @: https://www.datamintelligence.com/buy-now-page?report=contract-development-and-manufacturing-market?rk

Regional Break out:

☞ North America - US, Canada, Mexico

☞ Europe- Germany, Russia, UK, France, Italy, Rest of Europe

☞ Asia Pacific- China, India, Japan, Australia, Rest of Asia Pacific

☞ South America- Brazil, Argentina, Colombia, Rest of South America

☞ Middle East and Africa- Saudi Arabia, UAE, Oman, Bahrain, Qatar, Kuwait, Israel

📌 Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry/contract-development-and-manufacturing-market?rk

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Get 2-Day Free Trial + 50% OFF DataM Subscription@ https://www.datamintelligence.com/reports-subscription?rk

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.